Human Liver Model Market (By Product: 2D Models, 3D Models; By Application: ADME Studies, Toxicology Testing; By End-use: Academic & Research Institutes) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2024-2033

Human Liver Model Market Size and Growth

The global human liver mode market size was estimated at USD 1.21 billion in 2023 and it is expected to surpass around USD 4.42 billion by 2033, poised to grow at a CAGR of 13.83% from 2024 to 2033.

Key Pointers

• North America led the market with the largest market share of 42% in 2023.
• The Asia Pacific is expected to grow at the fastest CAGR during the forecast period.
• By Product, the 2D models segment registered the maximum market share of 83% in 2023.
• By Product, the 3D models segment is estimated to expand the fastest CAGR of 14.93% from 2024 to 2033.
• By Application, the ADME studies segment led the market with the largest revenue share of 40% in 2023.
• By Application, the toxicology testing segment is anticipated to grow at the noteworthy CAGR of 14.83% from 2024 to 2033.
• By End-use, the pharmaceutical and biotechnology segment captured the maximum market share of 49% in 2023.
• By End-use, the contract research organizations (CROs) segment is predicted to grow at the remarkable CAGR of 14.53% from 2024 to 2033.

Human Liver Model Market Overview

The human liver model market is experiencing significant growth due to the increasing demand for advanced models in drug discovery, toxicity testing, and disease modeling. These models are essential for understanding liver function and pathology, providing critical insights that can lead to the development of new treatments and therapies.

Human Liver Model Market Growth Factors

The growth of the human liver model market is propelled by an advancement in biotechnological methods, such as 3D bioprinting and organ-on-a-chip technologies, has significantly enhanced the accuracy and functionality of liver models, making them indispensable tools in drug discovery and toxicity testing. Additionally, the increasing prevalence of liver diseases like hepatitis, fatty liver disease, and liver cancer drives the demand for sophisticated liver models to better understand these conditions and develop effective treatments. Furthermore, the pharmaceutical industry's growing focus on reducing late-stage drug development failures by identifying hepatotoxicity early in the pipeline is boosting the adoption of these models. Collectively, these factors contribute to the robust expansion of the human liver model market.

What are the Trends in Human Liver Model Market?

• Adoption of 3D Bioprinting: The use of 3D bioprinting in creating liver models is on the rise. This technology allows for the development of more physiologically relevant liver tissues that closely mimic the human liver's architecture and functionality, enhancing research outcomes.
• Integration of Organ-on-a-Chip Technology: Organ-on-a-chip devices are gaining traction due to their ability to simulate the human liver's microenvironment and dynamic interactions. These devices are proving valuable in drug testing and disease modeling, offering more accurate and reliable data.
• Increased Focus on Personalized Medicine: There is a growing trend towards using liver models for personalized medicine. By developing patient-specific liver models, researchers can better predict individual responses to drugs and tailor treatments accordingly.
• Rising Investment in R&D: Substantial investment in research and development by pharmaceutical companies and academic institutions is driving innovation in liver model technologies. This investment is aimed at improving the accuracy and efficiency of drug discovery and toxicity testing processes.

What are the Key Challenges Faced by Human Liver Model Market?

• High Development Costs: Creating advanced liver models, such as 3D bioprinted tissues and organ-on-a-chip devices, involves significant financial investment. The high cost of development and maintenance can be a barrier to widespread adoption, particularly for smaller research institutions and companies.
• Technical Complexity: Developing and maintaining functional human liver models require specialized expertise and sophisticated technology. This technical complexity can limit the accessibility of these models to researchers and companies without the necessary resources and knowledge.
• Limited Standardization: There is a lack of standardization in the production and validation of human liver models. This variability can lead to inconsistent results, making it challenging to compare data across different studies and applications.
• Scalability Issues: Scaling up the production of advanced liver models to meet the increasing demand poses significant challenges. Ensuring consistent quality and functionality at larger scales can be difficult and may require further technological advancements.
• Ethical and Regulatory Hurdles: While human liver models offer a more ethical alternative to animal testing, they still face regulatory hurdles. Gaining approval from regulatory bodies for the use of these models in drug development and testing can be a lengthy and complex process.

What is the Contribution of North America to Human Liver Model Market?

North America dominated the human liver model market with the largest revenue share of 42% in 2023, due to several unique factors. The region benefits from a robust healthcare infrastructure and favorable regulatory environment that supports the adoption of advanced technologies such as human liver models for preclinical drug testing. North America boasts a high concentration of leading academic research institutions, biotech start-ups, and pharmaceutical companies that drive innovation and collaboration in liver disease research and drug development.

What is the Human Liver Model Market in U.S. from 2024 to 2033?

The U.S. human liver mode market size was valued at USD 0.35 billion in 2023 and is expected to hit around USD 1.29 billion by 2033, poised to grow at a CAGR of 13.83% from 2024 to 2033.

The human liver model market in the U.S. is anticipated to grow at the fastest CAGR during the forecast period. A strong emphasis on personalized medicine and the use of advanced technologies characterizes the U.S. market. The country's healthcare system encourages the adoption of innovative solutions, such as organ-on-a-chip devices, which can simulate the function of human livers. According to the CDC, 4.5 million adults aged 18 and older are living with liver disease in the U.S. Hence, the adoption of liver models is expected to increase in this country in the coming years.

The human liver model market in Europe is witnessing several notable trends. One significant trend is the increasing adoption of advanced technologies such as 3D bioprinting and organ-on-a-chip systems for developing more accurate and physiologically relevant liver models. These innovative technologies enable researchers to mimic the complex microenvironment of the liver, leading to improved drug testing and disease modeling capabilities.

The human liver model market in Asia Pacific is expected to grow at the fastest CAGR during the forecast period. One significant trend driving this growth is the increasing prevalence of liver diseases in the region, such as hepatitis and liver cancer, which has led to a higher demand for advanced research tools such as human liver models. Additionally, rising investments in healthcare infrastructure and research and development activities in China, Japan, and India fuel market expansion.

Product Insights

The 2D models segment led the market with the largest revenue share of 83% in 2023. This dominance is primarily due to the widespread adoption of 2D models in pharmaceutical research and drug development, owing to their cost-effectiveness and simplicity compared to more complex 3D models. Additionally, the ease of use and well-established protocols for 2D models make them a preferred choice for many researchers. The high demand for screening compounds for hepatotoxicity testing further supports the prevalence of 2D models, as they are efficient and reliable for various research applications.

The 3D models segment is projected to witness the fastest CAGR of 14.93% from 2024 to 2033, attributed to its ability to closely mimic the complex structure and function of the human liver. These models offer a more accurate representation of in vivo conditions, making them valuable tools for drug development, disease modeling, and personalized medicine. For example, Emulate Inc. offers organ-on-a-chip technology that recreates the microenvironment of human organs, including the liver, allowing for more precise testing of drug responses and toxicity levels.

Application Insights

Based on application, the ADME (absorption, distribution, metabolism, and excretion) studies segment led the market with the largest revenue share of 40% in 2023. The increasing demand for accurate and efficient drug development and testing processes drives this segment. By utilizing human liver models for ADME studies, researchers can simulate human physiological conditions more accurately, leading to better predictions of drug behavior in humans. Consequently, there is a high demand for liver models in the biopharmaceuticals industry, boosting the segment's growth.

The toxicology testing segment is projected to exhibit the fastest CAGR of 14.83% from 2024 to 2033. This growth can be attributed to the increasing demand for more accurate and predictive in vitro models to assess the safety and efficacy of new drug candidates, chemicals, and cosmetic ingredients. Pharmaceutical and chemical companies are increasingly adopting human liver models, such as 3D bioprinted liver tissues and organ-on-a-chip platforms, to replace traditional animal testing methods, which often fail to predict human-specific responses accurately. These factors are likely to drive the segment's growth.

End-use Insights

Based on end use, the pharmaceutical and biotechnology segment led the market with the largest revenue share of 49% in 2023. This dominance is primarily driven by the increasing demand for advanced liver models for drug development and toxicity testing within these industries. During preclinical studies, pharmaceutical and biotechnology companies rely heavily on human liver models to assess drug metabolism, drug-drug interactions, and hepatotoxicity. Using human liver models allows these companies to enhance the efficiency and accuracy of their drug development processes, leading to cost savings and reduced time-to-market for new pharmaceutical products.

The contract research organizations (CROs) segment is anticipated to witness the fastest CAGR of 14.53% from 2024 to 2033. The increasing demand for personalized medicine and the rising prevalence of liver diseases propel the need for advanced research and development in this field. CROs offer specialized services and expertise that pharmaceutical companies and research institutions can leverage to accelerate drug discovery processes related to liver diseases.

Who are the Top Manufactures in Human Liver Model Market?

• ATCC
• Merck KGaA
• AcceGen
• ZenBio, Inc.
• Organovo Holdings Inc.
• BioIVT
• InSphero
• Emulate, Inc.
• Mimetas
• CN Bio Innovations Ltd

Recent Developments

• CN Bio secured $21 million in Series B funding in April 2024 to address the rising interest in its organ-on-a-chip (OOC) technologies. This funding initiative is expected to significantly strengthen the company’s market position and accelerate the development and commercialization of its advanced liver models.
• In December 2023, CN Bio introduced its PhysioMimix assay specifically designed for non-alcoholic steatohepatitis (NASH). This assay was used to validate the effectiveness of INI-822, a drug developed by Inipharm. The introduction of this assay underscores the utility of organ-on-a-chip technology in liver disease research and drug development, providing a crucial tool for confirming drug efficacy.
• In September 2023, UC Davis Health launched a new program for liver transplants in adults. This program enhances the existing offerings of the UC Davis Transplant Center, providing comprehensive care to individuals with liver conditions and reinforcing the center's commitment to addressing liver disease through innovative solutions and advanced medical care.

Human Liver Model Market Segmentation:

By Product

• 2D Models
  • Cell lines
  • Primary Cells
• 3D Models
  • Liver on Chip
  • Organoids
  • Spheroids
  • Others

By Application

• ADME Studies
• Toxicology Testing
• Disease Modelling
• Others

By End-use

• Academic & Research Institutes
• Pharmaceutical & Biotechnology Companies
• Contract Research Organizations

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa